---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-001539"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2024-02-09T23:59:59+00:00"
generated_at: "2026-06-06T04:49:07.589119+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech reports Q1 net loss of $1.7M; secures up to C$23M govt funding for ARDS drug

## Summary
- Net loss $1.7M ($0.54/share) vs $2.3M ($0.89) YoY; operating expenses down to $1.9M from $2.4M.
- Cash and equivalents $4.3M at Dec 31, 2023; working capital $3.4M.
- Secured up to C$23M from Canadian government for EB05 ARDS Phase 3; regulators approved harmonized US/Canada trial.
- Planning Phase 2 for vitiligo (anti-CXCL10 mAb) and pulmonary fibrosis (EB05); seeking partnerships for dermatitis candidate EB01.

## SEC filing metadata
- accession: 0001654954-24-001539
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2024-02-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000165495424001539/0001654954-24-001539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000165495424001539/edsa_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-001539
- JSON: https://secwatch.observer/filing/0001654954-24-001539.json
- Plain text: https://secwatch.observer/filing/0001654954-24-001539.txt

## Key facts
- Earnings Releases
  Edesa Biotech, Inc. reported the three months ended December 31, 2023 results: net income a net loss of $1.7 million, or $0.54 per common share, EPS $0.54 per common share.
  - Period: the three months ended December 31, 2023
  - Net income: a net loss of $1.7 million, or $0.54 per common share
  - EPS: $0.54 per common share
  - Result: reported results
  source text: Edesa reported a net loss of $1.7 million, or $0.54 per common share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000165495424001539/0001654954-24-001539-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.